BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment
(2019)
Journal Article
Guazzelli, A., Meysami, P., Bakker, E., Demonacos, C., Giordano, A., Krstic- Demonacos, M., & Mutti, L. (2019). BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. International Journal of Molecular Sciences, 20(2), 429. https://doi.org/10.3390/ijms20020429
Malignant mesothelioma (MMe) is a cancer with poor prognosis and resistance to standard treatments. Recent reports have highlighted the role of the BRCA associated protein 1 gene BAP1 in the development of MMe. In this study, the chemosensitivity of... Read More about BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment.